Brief: Mabpharm Posts HY Loss Attributable RMB100 Million
25/08/2023 14:10
Aug 25 (Reuters) - Mabpharm Ltd 2181.HK :
* HY LOSS ATTRIBUTABLE RMB100 MILLION VERSUS LOSS RMB116.8
MILLION
* HY REVENUE RMB44.0 MILLION VERSUS RMB28.8 MILLION
Source text for Eikon: ID:nHKS5pmmF8
Further company coverage: 2181.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008